Search
01/03/2022
Effect of CPAP treatment on BP in resistant hypertensive patients according to the BP dipping pattern and the presence of nocturnal hypertension
Sapina-Beltran, E, Benitez, ID, Torres, G, Fortuna-Gutierrez, AM, Marquez, PP, Masa, JF, Drager, LF, Cabrini, M, Felez, M, Vazquez, S, Abad, J, Lee, C, Garcia-Rio, F, Casitas, R, Mediano, O, Peralta, SR, Martinez, D, Sanchez-de-la-Torre, M, Barbe, F, Dalmases, M. Effect of CPAP treatment on BP in resistant hypertensive patients according to the BP dipping pattern and the presence of nocturnal hypertension. HYPERTENSION RESEARCH. 2022; 45(3)DOI:10.1038/s41440-021-00762-7. PMID:34952953. IF:5.400(Q2/3D).
01/03/2022
Anxiety and body mass index affect asthma control: data from a prospective Spanish cohort
Baptista-Serna L., Rodrigo-Muñoz J.M., Mínguez P., Valverde-Monge M., Arismendi E., Barranco P., Barroso B., Bobolea I., Cañas J.A., Cárdaba B., Cruz M.J., Curto E., Domínguez-Ortega J., García-Latorre R., González-Barcala F.J., Martínez-Rivera C., Mullol J., Muñoz X., Olaguibel J.M., Picado C., Plaza V., Quirce S., Rial M.J., Sastre B., Soto L., Valero A., del Pozo V., Sastre J.. Anxiety and body mass index affect asthma control: data from a prospective Spanish cohort. Journal of Allergy and Clinical Immunology-In Practice. 2022; 10(3)DOI:10.1016/j.jaip.2021.10.013. PMID:34673289. IF:9.400(Q1/2D).
01/03/2022
Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial
Agusti, A, De Stefano, G, Levi, A, Munoz, X, Romero-Mesones, C, Sibila, O, Lopez-Giraldo, A, Moral, VP, Curto, E, Echazarreta, AL, Marquez, SE, Pascual-Guardia, S, Santos, S, Marin, A, Valdes, L, Saldarini, F, Salgado, C, Casanovas, G, Varea, S, Rios, J, Faner, R. Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. EUROPEAN RESPIRATORY JOURNAL. 2022; 59(3)DOI:10.1183/13993003.03036-2021. PMID:35144989. IF:24.300(Q1/1D).
01/03/2022
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Podzamczer, D, Mican, R, Tiraboschi, J, Portilla, J, Domingo, P, Llibre, JM, Ribera, E, Vivancos, MJ, Morano, L, Masia, M, Gomez, C, Fanjul, F, Payeras, A, Inciarte, A, Estrada, V, Rivero, A, Castro, A, Bernal, E, Vinuesa, D, Knobel, H, Troya, J, Macias, J, Montero, M, Sanz, J, Navarro-Alcaraz, A, Caicedo, A, Fernandez, G, Martinez, E, Moreno, S. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases. 2022; 9(3)DOI:10.1093/ofid/ofab595. PMID:35237700. IF:4.200(Q2/4D).